Breaking Finance News

A report released today by Zacks Investment Research about Agilent Technologies Inc (NYSE:A) ups the target price to $53.00

Zacks Investment Research bumped the target price of Agilent Technologies Inc (NYSE:A) to $53, indicating a possible upside of 0.11%.

On 8/18/2016, Robert W. Baird reported on Agilent Technologies Inc(NYSE:A) raised the target price from $48.00 to $52.00 that suggested an upside of 0.11%.

Yesterday Agilent Technologies Inc (NYSE:A) traded 1.43% lower at $47.58. A’s 50-day average is $47.17 and its 200-day average is $43.84. With the last stock price close up 2.18% relative to the two hundred day average, compared with the S&P 500 which has fallen -0.01% over the same period. Volume of trade was was up over the average, with 2,592,850 shares of A changing hands over the typical 2,036,900 shares..

Performance Graph:

Agilent Technologies Inc (NYSE:A)

With a market capitalization of $0.0, Agilent Technologies Inc has a one-year low of $33.12 and a one-year high of $48.63 with a PE ratio of 31.

Also covering Agilent Technologies Inc’s stock price target, a total of 14 equity analysts have released a report on A. The average target price is $45.86 with six firms rating the stock a strong buy, four analysts rating the company a buy, six analyts rating the stock a hold, 0 rating the company to underperform, and lastly 0 analystsrating the company as sell.

General Company Details For Agilent Technologies Inc (NYSE:A)

Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, and genomics and the nucleic acid solutions businesses. Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *